Report on the risk assessment of 1-(3-chlorophenyl)-2-(methylamino)propan-1-one (3-chloromethcathinone, 3-CMC) in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended)

Lisbon March 2022

Series type: Risk assessments

Summary

This publication presents the data and findings of the risk assessment on 1-(3-chlorophenyl)-2-(methylamino)propan-1-one (3-chloromethcathinone, 3-CMC), carried out by the extended Scientific Committee of the EMCDDA on 19 November 2021. On the basis of the Risk Assessment Report, on 18 March 2022, the Commission decided that 3-CMC should be included in the definition of 'drug', in the Annex to Framework Decision 2004/757/JHA. 

Download as PDF

Table of contents

  • Acknowledgements
  • Foreword
  • EMCDDA Initial Report on 1-(3-chlorophenyl)-2-(methylamino)propan-1-one (3-chloromethcathinone, 3-CMC)
  • Risk assessment report on a new psychoactive substance: 1-(3-chlorophenyl)-2-(methylamino)propan-1-one (3-chloromethcathinone, 3-CMC)
  • Annex 1: Technical report on the new psychoactive substance 1-(3-chlorophenyl)-2-(methylamino)propan-1-one (3-chloromethcathinone, 3-CMC)
  • Annex 2: Participants of the risk assessment meeting, 19 November 2021
Cover of the 3-CMC risk assessment
Pub. Author: 
EMCDDA
Issue: 
35
Pages: 
90
Price: 
free
ISBN: 
978-92-9497-703-8
ISSN: 
1725-4493
Pub. DOI: 
10.2810/671114
Catalog Number: 
TD-AK-22-003-EN-N

Related links: 

Main subject

NPS

Keywords

3-CMC
early warning system
NPS
synthetic cathinones
synthetic drugs
toxicology

Target audience

policymaker
researcher

Publications

Loading